Australia’s first clinical trials of an investigational gene therapy for dry age-related macular degeneration (AMD) has commenced at the Centre for Eye Research Australia (CERA). Read more
The Therapeutic Goods Administration (TGA) has confirmed a shortage of Prednefrin Forte 10mL eye drops in Australia, which isn’t expected to be available until January next year, but its supplier has confirmed it is working towards providing an alternative product. Read more
An independent expert panel has recommended Novartis’ treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related macular degeneration (nAMD) patients as a second-line anti-VEGF treatment. Read more
Two years since the KeepSight launch, Insight asks what measurable difference this once-in-a-generation program is making to those living with the diabetes.
Nova Eye Medical has published two-year data for its iTrack ab-interno canaloplasty procedure, which it says showed an average reduction in mean intraocular pressure (IOP) of 30%, irrespective of whether it was performed standalone or with cataract surgery. Read more
The term ‘quarantine myopia’ has been coined to describe what appears to be a worsening of the condition in many paediatric patients due to lockdowns across the world. RHIANNON BOWMAN asks whether Australian optometrists and parents should be worried. Read more
The managing director of one of Australia’s pre-eminent eye research institutions is a leading scientist behind experiments on mice that have shown promise for developing new gene therapies for both glaucoma and dementia. Read more
A new diabetic eye clinic for children in Western Australia, which opened last month, is part of the Lions Eye Institute’s first major clinical-research platform for children’s eye health.
Nova Eye Medical has announced positive five-year follow-up data from a sub-study analysis of the multi-centre LEAD trial for its 2RT nano-pulse ophthalmic laser therapy. Read more
Advances in glaucoma stent technology far outstripped the Medicare schedule early on, creating a disconnect that had far-reaching consequences. As Australia marks World Glaucoma Week this 7-13 March, Insight traces the turbulent MBGS journey that’s now considered an ophthalmology success story.